文献速递前列腺癌

局限性前列腺癌不可逆电穿孔的理想候选者:EAU腔内泌尿学分会综合叙述性综述

Identifying the ideal candidate for irreversible electroporation in localized prostate cancer: a comprehensive narrative review from the EAU Section of Endourology.
PubMed 文献 · BJU Int · 2026-08-26

本叙述性综述(2014-2025)汇总了原发性不可逆电穿孔(IRE)治疗局限性前列腺癌的前瞻性系列、多中心登记、比较研究和系统综述,旨在界定理想候选者。理想候选者为单侧MRI可见、器官局限的ISUP 2-3级病变,病灶通常≤20 mm,PSA密度<0.15-0.20 ng/mL/cm3;现场消融临床显著癌约80-90%,但野外复发约15-25%。

要点

  • 理想候选者为单侧MRI可见、器官局限的ISUP 2-3级前列腺癌,病灶通常≤20 mm。
  • 现场消融临床显著癌约80-90%,但野外复发占失败病例约15-25%。
  • 半腺IRE的临床显著癌持续率8.6%优于局灶消融的25%,但局灶消融更好地保留勃起功能。

核心结论

  • 原发性IRE在选择的局限性前列腺癌患者中安全有效,理想候选者具有单侧MRI可见、器官局限的ISUP 2-3级病变。
  • 半腺模板可能提高肿瘤学可靠性,而局灶消融最大化功能结局。

研究设计与样本

  • 叙述性综述(2014-2025),纳入原发性IRE治疗局限性前列腺癌的前瞻性系列、多中心登记、比较研究和系统综述。

主要发现

  • 现场消融临床显著癌约80-90%,功能保留率高。
  • 主要局限为野外复发,约占失败病例的15-25%,反映前列腺癌多灶性。
  • PRESERVE试验中12个月现场持续率约16%。
  • 半腺IRE的临床显著癌持续率为8.6%,局灶消融为25%,但局灶IRE更好地保留勃起功能。

关键数值与推荐

  • 理想候选者:单侧MRI可见、器官局限的ISUP 2-3级病变,PSA密度<0.15-0.20 ng/mL/cm3,病灶小到足以可靠电极覆盖。
  • 当前证据和电极几何形状支持靶病灶一般≤20 mm。

临床怎么用

  • 选择单侧MRI可见、器官局限的ISUP 2-3级、PSA密度<0.15-0.20 ng/mL/cm3且病灶≤20 mm的患者。
  • 根据肿瘤学与功能权衡选择半腺或局灶消融模板。
  • 治疗后需随访监测野外复发。

局限性

  • 比较证据有限,主要来自单一研究。
  • 叙述性综述设计,非系统评价。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Irreversible electroporation (IRE) is an emerging non-thermal focal therapy for localized prostate cancer (PCa), offering tissue-selective ablation with functional preservation. This review aimed to delineate the 'ideal' candidate for primary IRE and provide practical guidance. METHODS: A narrative review (2014-2025) of primary IRE for localized PCa was conducted, including prospective series, multicentre registries, comparative studies, and systematic reviews. We synthesized baseline characteristics, lesion features, ablation strategy, oncologic/functional outcomes, and complications, focusing on cancer control and safety. RESULTS: The best outcomes were reported in men with magnetic resonance imaging-visible, organ-confined intermediate-risk (International Society for Urological Pathology [ISUP] 2-3) PCa, typically presenting a single dominant unilateral index lesion characterized by multiparametric MRI and biopsy. Contemporary series show in-field ablation of clinically significant cancer in ~80-90% with high functional preservation. The main limitation is out-of-field recurrence (~15-25% of failures), reflecting PCa multifocality. In-field persistence at 12 months was ~16% in the PRESERVE trial. Lesion size is a key practical constraint; current evidence and electrode geometry favour targets generally ≤20 mm. Limited comparative evidence, largely from a single study, suggests better oncologic control with hemi-gland IRE (clinically significant PCa persistence 8.6%) versus focal ablation (25%), whereas focal IRE better preserves erectile function. CONCLUSIONS AND CLINICAL IMPLICATIONS: Primary IRE appears safe and effective in selected localized PCa. The ideal candidate has unilateral MRI-visible, organ-confined ISUP 2-3 disease, prostate-specific antigen density <0.15-0.20 ng/mL/cm3, and a lesion small enough for reliable electrode coverage. Hemi-gland templates may improve oncologic reliability, whereas focal ablation maximizes functional outcomes. PATIENT SUMMARY: IRE is a focal, non-thermal treatment for localized PCa that can control the treated lesion while usually preserving urinary continence and often erectile function. Cancer can still occur elsewhere in the prostate after treatment, so follow-up is essential.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. La Mura R, Maiolino G, Anract J, et al. Identifying the ideal candidate for irreversible electroporation in localized prostate cancer: a comprehensive narrative review from the EAU Section of Endourology. BJU Int. 2026. PMID: 42643154. doi:10.1111/bju.70436

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。